archive · today in ai · 2026-07-20

Tempus AI to acquire Personalis for $1.5B

Archive item — written before sources were shown.

Tempus AI agreed to buy cancer-genomics firm Personalis for about $1.5 billion in stock, adding disease-monitoring tech to its precision-oncology platform.

By Rami Steitieh Monday, 20 July · 20:00 UTC Read 1 min · 1 source

Tempus AI agreed to acquire cancer-genomics company Personalis for roughly $1.5 billion, paying $16.25 per share primarily in Tempus stock with an option to pay up to half in cash. The deal folds Personalis’ molecular residual disease testing, which tracks trace cancer DNA after treatment, into Tempus’ AI-driven precision-oncology platform. Both boards have approved the transaction, which is expected to close in late 2026 or early 2027 pending shareholder and regulatory approval.

sources

01Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platformtempus.com · primary

Rami Steitieh

Builder and operator. Runs 17 content sites and Trilot LLC on the tools reviewed here.

About Rami How we verify Email